Last reviewed: June 30, 2026 Last updated: June 30, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Sistani joined WeightWatchers in 2022 and led the company for about two-and-a-half years
GLP-1 Safety: Serious Risks and Warning Signs Less common risks can affect eligibility, monitoring, and when to seek care
In other words, these improvements would occur even without the medication
The broader regulatory environment for compounded GLP-1s is the most important context for any buyer evaluating this category right now - not just for Omzo, but for every platform in this space
Its estimated that this expanded coverage may cover 10 percent of Medicare beneficiaries